Summary:
- The article discusses the U.S. Food and Drug Administration's (FDA) decision to refuse reviewing the effectiveness of the influenza vaccine, despite evidence suggesting the vaccine may not be as effective as claimed.
- It highlights the concerns raised by the Center for Infectious Disease Research and Policy (CIDRAP) about the lack of transparency and oversight in the flu vaccine approval process, which could impact public trust in the vaccine.
- The article suggests that the FDA's decision to forgo a review of the flu vaccine's effectiveness goes against the principles of evidence-based decision-making and may have significant implications for public health.